http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유형민(Hyung Min Yu),조용근(Yong Geun Cho),권지운(Jiwoon Kwon),한승오(Seung Oh Han) 대한기계학회 2021 대한기계학회 춘추학술대회 Vol.2021 No.4
로봇암의 회전 토크를 높이기 위해 사용되는 감속기는 모터, 모션 제어기와 함께 산업용 협동 로봇의 3 대 핵심 부품으로써 로봇의 성능을 결정하는 하나의 중요한 요소이다. 따라서 감속기의 신뢰성은 로봇의 수명을 결정하는 핵심 요소이며 전세계적으로 유명한 선진사 제품의 감속기는 30,000 시간 이상의 내구성을 보증한다. 본 연구에서는 선진사의 감속기 내구 수명을 분석하여 향후 국산 제품의 내구 수명을 결정하는 각 파라미터의 기준을 제시하기 위해 가속계수를 적용한 벤치 테스트를 통해 감속기 표면에서 발생하는 온도와 시험 종료 후 초기 감속비 유지 여부를 분석하였다. 가속계수는 Weibull분포에 기반한 평균 무고장 시간을 산출하고, 하모닉 드라이브의 허용 토크를 고려하여 산출되었으며 시험 결과 감속비의 오차는 5% 미만, 표면 온도는 안정구간에서 60℃를 유지하였다. Harmonic reducer used to enhance the torque of robot arm is one of the core part applied to collaborative industrial robot, and therefore the reliability of this part is crucial to determine the robot performance. In this study, reduction ratio and surface temperature was suggested as parameters to define the functional failure in reliability perspective. The harmonic reducer produced by leading company was studied experimentally by accelerated life testing technique for analyzing the suggested parameters. Acceleration factor was obtained by mean time between failure (MTBF) based on Weibull distribution with consideration of allowable torque for harmonic drive. It was noted that the discrepancy of the reduction ratio is less than 5% and the temperature is maintained at 60℃ in the steady state. Consequently, this result can be used in new reducer development as reliability criteria.
비대상성 간경변이 호전된 간세포암종에서 경동맥화학색전술과 고주파열치료술로 병합치료한 증례
유형민 ( Hyung Min Yu ),최원혁 ( Won Hyeok Choe ),권소영 ( So Young Kwon ),김정한 ( Jeong Han Kim ) 대한간암학회 2014 대한간암학회지 Vol.14 No.2
Case Reports : A Case of Hepatocellular Carcinoma with Improved Decompansated Liver Cirrhosis with Combination Treatment of Transarterial Chemoembolization and Radiofrequency Ablation
소라페닙 투여 간세포암종 환자에서 항바이러스제 치료의 생존이득
김정한 ( Jeong Han Kim ),유형민 ( Hyung Min Yu ),황용 ( Yong Hwang ),고순영 ( Soon Young Ko ),최원혁 ( Won Hyeok Choe ),권소영 ( So Young Kwon ) 대한간암학회 2016 대한간암학회지 Vol.16 No.1
Background/Aims: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has been shown to improve survival of advanced HCC patients. Whether antiviral therapy with NAs could help such patients is unknown. Our aim is to investigate the usefulness of antiviral therapy for advanced-stage HCC treated with sorafenib. Methods: We performed a retrospective cohort study in advanced-stage HCC patients treated with sorafenib between June 2007 and December 2013. Patients in group A (the nonantiviral therapy group) were treated with sorafenib alone. Those in group B (the antiviral therapy group) were treated with sorafenib and NAs. Progression-free survival (PS) and overall survival (OS) were compared between these two groups. Results: Finally, 23 patients in group A and 40 patients in group B were enrolled in the study. The mean number of days of treatment with sorafenib was 79 (34-231) days and 96 (33-449) days for group A and B, respectively (P=0.286). The mean PS of group A and B was 97 (14-449) days and 51 (0-461) days, respectively (P=0.068). The OS was 154 (44-741) days in group A and 138 (30-1,025) days in group B (P=0.665). PS and OS showed no significant difference between the two groups. Conclusions: This study shows that there was no significant survival gain of using antiviral therapy in patients with advanced-stage HCC treated with sorafenib. In consideration of costeffectiveness, antiviral therapy may be not mandatory. (J Liver Cancer 2016;16:23-30)
박수연 ( Su Youn Park ),유형민 ( Hyung Min Yu ),김지완 ( Ji Wan Kim ),안상희 ( Sang Hee An ),김욱연 ( Wook Youn Kim ),허미나 ( Mina Hur ),이홍기 ( Hong Gi Lee ) 대한내과학회 2014 대한내과학회지 Vol.86 No.6
이식 후 림프증식 질환은 이식 환자에서 면역 억제로 인하여 나타나는 치명적 부작용으로서 보통 Epstein-Barr 바이러스 (EBV) 감염에 따른 저항력 약화가 발생 원인으로 추정된다. 36세 남자가 혈관면역모세포 T세포림프종 치료를 위한 자가 조혈모세포이식 후 673일째 오한, 발열을 주소로 내원하여 다발성 림프절 비대가 발견되었다. 조직검사 및 면역화학염색으로 Reed-Sternberg 세포와 EBV를 확인하였으며 호지킨 림프종으로 진단되었다. 총 8주기의 ABVD 복합 항암화학요법을 시행하였으며 잔단 후 15개월이 경과한 현재 완전관해 상태를 유지하고 있다. 본 증례는 자가조혈모세포 이식 후 발생한 호지킨림프종으로 국내에서는 첫 보고 사례이다. Post-transplantation lymphoproliferative disorder (PTLD) is a serious complication that can develop after either solid organ or hematopoietic stem cell transplantation (HSCT). The incidence of Hodgkin`s lymphoma (HL) ranges from 0.5-1.0% of PTLD after HSCT without T-cell depletion. Here, we report a case of HL-PTLD that occurred after autologous peripheral blood stem cell transplantation for an angioimmunoblastic T-cell lymphoma (AITL). A 36-year-old patient developed fever and chills with multiple lymphadenopathies at day 673 after auto-HSCT for AITL. Three months after the transplant, the patient developed fever with elevated plasma Epstein-Barr virus (EBV)-PCR values. The excisional biopsy revealed HL at Ann Arbor stage IIIB. A total of 8 cycles of chemotherapy with ABVD please define were performed, and the patient has remained disease-free. To our knowledge, this is first case report of HL-PTLD after auto-PBSCT in Korea. (Korean J Med 2014;86:774-780)
뇌전이를 동반한 간세포암종 환자에서 수술 절제 후 장기 생존을 보인 1예
이정호 ( Jeong-ho Lee ),유형민 ( Hyung-min Yu ),조성범 ( Sung-bum Cho ) 대한간암학회 2016 대한간암학회지 Vol.16 No.1
Brain metastasis is a rare condition of extraheptaic metastases in hepatocellular carcinoma (HCC). Patients with hepatocellular carcinoma and brain metastasis have rapidly worsened neurologic signs and symptoms, therefore it is regarded to oncologic emergency. Current recommended treatments for brain metastasis are surgical resection or gamma-knife surgery with/without whole brain radiation therapy (RT). However, patients with brain metastasis have a very poor prognosis after adequate treatment. Here, we report a 62-year-old man with HCC and brain metastasis who had long term survival after surgical resection and whole brain RT. (J Liver Cancer 2016;16:38-41)
증례 : 혈액종양 ; 무도병을 주소로 내원한 진성적혈구증가증 1예
김선웅 ( Sun Woong Kim ),유형민 ( Hyung Min Yu ),이윤정 ( Yoon Jeong Lee ),김희진 ( Hee Jin Kim ),허미나 ( Mina Hur ),이홍기 ( Hong Ghi Lee ) 대한내과학회 2014 대한내과학회지 Vol.87 No.5
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Clinical symptoms can range in severity from headache and tinnitus to thrombohemorrhagic complications. Neurologic symptoms are common at the onset of polycythemia; however, chorea due to PV is a rare complication. We present the case of a 77-year-old female who was referred to our hospital because of choreic movement of the limbs, head and face. She was diagnosed with JAK2V617F mutation-positive PV. Her chorea was completely resolved by phlebotomy combined with hydroxyurea and aspirin. (Korean J Med 2014;87:619-624)
폐전이를 보인 단일결절형 거대 간세포암종 환자에서 순차적인 경동맥화학색전술과 Sorafenib으로 완전관해를 보인 1예
김기현 ( Gi-hyun Kim ),유형민 ( Hyung-min Yu ),임채준 ( Chae-june Lim ),조성범 ( Sung-bum Cho ) 대한간암학회 2016 대한간암학회지 Vol.16 No.1
Current guidelines recommend sorafenib as the first-line molecular target agent for advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis and unresectable HCC. Sorafenib was reported to show survival benefit for patients with advanced HCC. However, complete response is extremely rare in patients treated with sorafenib. Here, we report a 52-year-old man with advanced HCC and pulmonary metastasis who showed complete response by sequential transarterial chemoembolization and continuous sorafenib. Complete response was sustained for 53-month until now. (J Liver Cancer 2016;16:47-51)